We are live on
!
Find out more
CRB
Chad R. Baker Portfolio holdings
AUM
$620M
1-Year Est. Return
42.67%
This Fund
S&P 500
This Quarter
Est. Return
+12.61%
1 Year Est. Return
+42.67%
3 Year Est. Return
+108.31%
5 Year Est. Return
+132.07%
10 Year Est. Return
+563.15%
AUM
$538M
AUM Growth
+$47.3M
(+9.6%)
Cap. Flow
-$283K
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.99%
Holding
50
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$189K |
| 2 |
Amphenol
APH
|
+$93.7K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.55% |
| 2 | Industrials | 21.7% |
| 3 | Healthcare | 15.98% |
| 4 | Consumer Discretionary | 12.32% |
| 5 | Communication Services | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Norfolk Southern
NSC
$75.6B
| $8.68M | 1.61% |
33,906
| – | – |
|
27
Procter & Gamble
PG
$347B
| $8.4M | 1.56% |
52,710
| – | – |
|
28
New York Times
NYT
$12.3B
| $8.02M | 1.49% |
143,325
| – | – |
|
29
Home Depot
HD
$331B
| $7.9M | 1.47% |
21,545
| – | – |
|
30
TJX Companies
TJX
$171B
| $7.7M | 1.43% |
62,340
| – | – |
|
31
Stryker
SYK
$123B
| $7.58M | 1.41% |
19,170
| – | – |
|
32
Lowe's Companies
LOW
$115B
| $6.23M | 1.16% |
28,100
| – | – |
|
33
RTX Corp
RTX
$265B
| $5.6M | 1.04% |
38,348
| – | – |
|
34
Salesforce
CRM
$143B
| $4.78M | 0.89% |
17,525
| – | – |
|
35
Colgate-Palmolive
CL
$73.1B
| $4.65M | 0.86% |
51,200
| – | – |
|
36
CRISPR Therapeutics
CRSP
$4.69B
| $4.53M | 0.84% |
93,205
| – | – |
|
37
Vertex Pharmaceuticals
VRTX
$123B
| $4.34M | 0.81% |
9,740
| – | – |
|
38
Alphabet (Google) Class C
GOOG
$4.3T
| $3.92M | 0.73% |
22,100
| – | – |
|
39
Zoetis
ZTS
$31.9B
| $3.87M | 0.72% |
24,818
| – | – |
|
40
Adobe
ADBE
$93.5B
| $3.48M | 0.65% |
9,000
| – | – |
|
41
CSX Corp
CSX
$92.9B
| $3.33M | 0.62% |
102,000
| – | – |
|
42
Airbnb
ABNB
$86.3B
| $3.17M | 0.59% |
23,955
| – | – |
|
43
McCormick & Company Non-Voting
MKC
$14B
| $2.61M | 0.48% |
34,370
| – | – |
|
44
Arm
ARM
$291B
| $1.97M | 0.37% |
12,155
| – | – |
|
45
ExxonMobil
XOM
$617B
| $1.77M | 0.33% |
16,400
| – | – |
|
|
46
Cigna
CI
$75.1B
| $1.74M | 0.32% |
5,254
-587
| -10% | -$189K |
|
47
NVIDIA
NVDA
$4.94T
| $1.55M | 0.29% |
9,795
| – | – |
|
48
Merck
MRK
$309B
| $1.24M | 0.23% |
15,700
| – | – |
|
49
Becton Dickinson
BDX
$43B
| $934K | 0.17% |
5,420
| – | – |
|
|
NVO
50
Novo Nordisk
NVO
$221B
| $332K | 0.06% |
4,815
| – | – |
|
Similar funds
RC
TTSTC
KFAS
RIS
AMG
BWP
MC
ACP
Chad R. Baker's Q2 2025 Portfolio in Review
As of Q2 2025, Chad R. Baker held 50 positions worth $538M, up 9.6% from $491M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Trading was light in Q2 2025: portfolio turnover was 0%. Chad R. Baker opened no new positions and made no exits, leaving the 50-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 28% a quarter earlier, followed by Industrials and Healthcare.
- Chad R. Baker's biggest Q2 2025 reduction was Cigna, cutting an estimated $189K.
- Chad R. Baker's ten largest holdings make up 44% of its $538M portfolio in Q2 2025.
- Chad R. Baker opened 0 new positions and closed 0 in Q2 2025.
- Chad R. Baker's portfolio value rose 9.6% quarter-over-quarter to $538M.
Based on Chad R. Baker's 13F filing for Q2 2025, filed 11 Jul 2025.